The vaccine was launched with a duration of immunity (DOI) of 16 weeks for M. hyo, but this has been increased to 23 weeks after Zoetis successfully repeated the registration trial.

Suvaxyn Circo+MH RTU

“One of the original registration studies for efficacy of the vaccine was disrupted by a PRRS outbreak before the full DOI for M. hyo could be demonstrated,” Zoetis UK’s National Veterinary Manager, Dr Laura Hancox BVetMed PhD MRCVS, said. “When Suvaxyn Circo+MH RTU (ready-to-use) was launched in Europe late last year, we could only claim a DOI of 16 weeks, but now the trial has been repeated, this has been increased to 23 weeks.

“With the existing 23-week DOI for PCV2, this study has proven a single 2ml shot of Suvaxyn Circo+MH RTU provides lifelong M. hyo and circovirus cover in finishing pigs. It now boasts the longest DOI of any one-shot, RTU vaccine for these two conditions on the market.”

A true bivalent vaccine built from the ground up, and not just two existing products mixed together, Suvaxyn Circo+MH RTU is manufactured in a process that uses aspects of human vaccine technology. Treatment is possible from three weeks of age, with the onset of immunity to both PCV2 and M. hyo three weeks after vaccination.

Clinical trials have shown it reduces faecal shedding caused by PCV2 infection, as well as reducing the viral load in blood and lymphoid tissues. It also reduces lung lesions caused by M. hyo infection.

Dr Hancox said the studies had shown similar levels of protection against M. hyo despite the time between vaccination and disease challenge.

“In the trials, pigs vaccinated at three-weeks old were challenged by M. hyo either six weeks, 16 weeks or 23 weeks after vaccination,” she added. “Lung lesions seen four weeks after M. hyo challenge were very similar independent of the time between vaccination and challenge, indicating that whenever the M. hyo challenge arises Suvaxyn Circo+MH RTU gives consistent protection throughout the lifetime of the finishing pig.

As well as its proven efficacy, the one-shot Suvaxyn Circo+MH RTU vaccination provides the additional benefits of reduced stress for the pigs and decreased labour time needed for treatment, as only a single injection is required.

Suvaxyn Circo+MH RTU Emulsion for Injection for Pigs contains inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein and inactivated Mycoplasma hyopneumoniae, strain P-5722-3. For active immunisation of pigs against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae. POM-V

For further information please see the product’s SPC or please contact your veterinary surgeon or Zoetis UK Limited, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS. www.zoetis.co.uk Customer Support: 0845 300 8034. Use medicines responsibly (www.noah.co.uk/responsible). Date of preparation: July 2017. AH177/17

You can visit our PMWS/PCVAD page by clicking here.